Erudio Healtherudio.com
Drug
Anitocabtagene autoleucel trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying anitocabtagene autoleucel: iMMagine-3. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 1 more trial with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| iMMagine-3 NCT06413498 · Kite, A Gilead Company | relapsed/refractory multiple myeloma | Phase 3 | 159 | 24 | Standard | Nov 14, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| iMMagine-1 NCT05396885 · Kite, A Gilead Company DeepView → | relapsed or refractory multiple myeloma | Phase 2 | Deep | View | |||